These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19590498)

  • 21. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type.
    Bellew KM; Pigeon JG; Stang PE; Fleischman W; Gardner RM; Baker WW
    Alzheimer Dis Assoc Disord; 2004; 18(4):208-13. PubMed ID: 15592132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease.
    Ito T; Meguro K; Akanuma K; Meguro M; Lee E; Kasuya M; Ishii H; Mori E
    J Clin Neurosci; 2007 Sep; 14(9):850-5. PubMed ID: 17587584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
    Hanon O; Berrou JP; Negre-Pages L; Goch JH; Nádházi Z; Petrella R; Sedefdjian A; Sévenier F; Shlyakhto EV; Pathak A
    J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
    Brousseau G; Rourke BP; Burke B
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.
    Lu PH; Masterman DA; Mulnard R; Cotman C; Miller B; Yaffe K; Reback E; Porter V; Swerdloff R; Cummings JL
    Arch Neurol; 2006 Feb; 63(2):177-85. PubMed ID: 16344336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Navigating patients and caregivers through the course of Alzheimer's disease.
    Aupperle PM
    J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood pressure, dementia and Alzheimer's disease: the OPTIMA longitudinal study.
    Razay G; Williams J; King E; Smith AD; Wilcock G
    Dement Geriatr Cogn Disord; 2009; 28(1):70-4. PubMed ID: 19648748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2.
    Plastino M; Fava A; Pirritano D; Cotronei P; Sacco N; Sperlì T; Spanò A; Gallo D; Mungari P; Consoli D; Bosco D
    J Neurol Sci; 2010 Jan; 288(1-2):112-6. PubMed ID: 19836029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
    Cummings J; Jones R; Wilkinson D; Lopez O; Gauthier S; Waldemar G; Zhang R; Xu Y; Sun Y; Richardson S; Mackell J
    J Alzheimers Dis; 2010; 21(3):843-51. PubMed ID: 20634594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The existence of cognitive plateaus in Alzheimer's disease.
    Bozoki AC; An H; Bozoki ES; Little RJ
    Alzheimers Dement; 2009 Nov; 5(6):470-8. PubMed ID: 19896586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive treatments, cognitive decline, and dementia.
    Duron E; Hanon O
    J Alzheimers Dis; 2010; 20(3):903-14. PubMed ID: 20182022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing motor and cognitive regulation in AD, MCI, and controls using the Behavioral Dyscontrol Scale.
    Belanger HG; Wilder-Willis K; Malloy P; Salloway S; Hamman RF; Grigsby J
    Arch Clin Neuropsychol; 2005 Mar; 20(2):183-9. PubMed ID: 15708728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical utility of the Mattis Dementia Rating Scale in assessing cognitive decline in Alzheimer's disease.
    Miller JM; Pliskin NH
    Int J Neurosci; 2006 May; 116(5):613-27. PubMed ID: 16644521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homocysteine as a predictor of cognitive decline in Alzheimer's disease.
    Oulhaj A; Refsum H; Beaumont H; Williams J; King E; Jacoby R; Smith AD
    Int J Geriatr Psychiatry; 2010 Jan; 25(1):82-90. PubMed ID: 19484711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults.
    Reger MA; Henderson ST; Hale C; Cholerton B; Baker LD; Watson GS; Hyde K; Chapman D; Craft S
    Neurobiol Aging; 2004 Mar; 25(3):311-4. PubMed ID: 15123336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.